Case Reports in Psychiatry
2026
Ridhi J. Vyas, Ryan Hood, Jeremy Hsiang et al.
3,4‐Methylenedioxymethamphetamine (MDMA)‐assisted psychotherapy (MDMA‐AP) has shown promise in treating post‐traumatic stress disorder (PTSD), particularly in treatment‐resistant cases. However, little is known about its potential to precipitate adverse psychiatric outcomes. We present the case of a 31‐year‐old woman with nondistressing childhood compulsions, chronic PTSD, and complex medical...
Case Reports in Psychiatry
2026
Maxwell Angel
Introduction: Obsessive-compulsive disorder (OCD) is a chronic psychiatric condition that frequently presents with comorbid depressive disorders. For patients exhibiting treatment-refractory OCD and concurrent depressive disorder(s), there is growing clinical interest in the noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist ketamine as a rapid-acting intervention. This case report...
Case Reports in Psychiatry
2025
Alok Atreya, Sabbu Maharjan, Samata Nepal et al.
1 citation
Possession state is a disorder of consciousness with substitution of the personality, which is claimed to be a spirit, a deity, a dead person or some other power. In rural Nepal these experiences are normalised and Hindu communities often attribute psychological conditions to a supernatural cause. We report the case of a 30-year-old woman who presented with acute-onset symptoms characterised by...
Case Reports in Psychiatry
2024
Richard C. J. Bradlow, Sophie Wright, Anamaria Szrajbman Vaz da Silva et al.
3 citations
Introduction: There has been a recent significant increase in medical cannabis prescribing in Australia despite weak evidence for its effectiveness in treating the most common indications. Concern has been raised about the potential harms of inappropriate prescription of cannabis; however, there have been no prior published cases of psychosis secondary to medicinal cannabis in Australia. Case...
Case Reports in Psychiatry
2024
Jai Ahuja, Luba Leontieva
This case report examines the unexpected increase in suicidal ideation following ketamine infusion therapy in a 75-year-old female with a history of treatment-resistant depression. Despite ketamine's established efficacy in treating depression and acute suicidality, this patient's condition deteriorated posttreatment. The report delves into the patient's complex background, including...
Case Reports in Psychiatry
April 26, 2022
Jeremy Weleff, Kelly A. Bryant, Alexsandra Kovacevich et al.
5 citations
Background. Clinical trials have demonstrated that subanesthetic intravenous ketamine exerts antidepressant effects lasting a week or longer postinfusion, as well as antisuicidal effects starting approximately 4 hours postinfusion and lasting 72 hours or longer. These findings have generated considerable enthusiasm within psychiatry. However, reports of treatment-emergent suicide attempts and...
Case Reports in Psychiatry
August 13, 2021
Sulochana Joshi, Anusha Manandhar, Pawan Sharma
10 citations
Meditation is regarded as a self-regulation approach to manage emotions. Meditation has a beneficial effect on mental health. Different kinds of meditation are practiced in many religions and cultures for the general wellbeing of an individual. However, meditation-related experiences and negative effects of meditation are not uncommon. Meditation-induced psychosis has been reported in the past....
Case Reports in Psychiatry
January 29, 2017
Joan M. Striebel, E. Nelson, Raj K. Kalapatapu
Methoxetamine (MXE) is a ketamine analogue with a high affinity for the N-methyl-D-aspartate (NMDA) receptor. MXE is a newly emerging designer drug of abuse and is widely available through on-line sources and is not detected by routine urine drug screens. In this report, we describe a United States (US) veteran with posttraumatic stress disorder (PTSD) and heavy polysubstance use, who injected...